XBP1 and breast carcinoma: In addition, the frequency of Eomes+ IFN-γ+/CD3+ CD8+ T cells was increased in response to breast cancer (MDA-MB231, Figure 7A), pancreatic cancer (Panc1, Figure 7B) or colon cancer (SW480, Figure 7C) cells in the lenalidomide treated XBP1-CTL.